 Home > Encyclopedia > Risedronate sodium

Risedronate sodium

Risedronate sodium structure

CAS No:
115436-72-1
Formula:
C7H11NO7P2.Na
Chemical Name:
Risedronate sodium
Synonyms:
Phosphonic acid,P,P′-[1-hydroxy-2-(3-pyridinyl)ethylidene]bis-,sodium salt (1:1);Phosphonic acid,[1-hydroxy-2-(3-pyridinyl)ethylidene]bis-,monosodium salt;Risedronate sodium;Actonel;NE 58095;Risedronic acid monosodium salt;Sodium risedronate;3-Pyridyl-1-hydroxyethylidene-1,1-biphosphonic acid sodium salt;Gemfos;Fossical;Atelvia;122458-82-6;1159813-51-0
Categories:
Organic Chemistry > Phosphines

Description

Fine White to Off-White Crystalline PowderRisedronate sodium is a nitrogen-containing bisphosphonate that inhibits osteoclast-mediated bone resorption and modulates bone metabolism. Risedronate sodium is used for the treatment of postmenopausal osteoporosis to reduce the risk of vertebral fractures, treatment of established postmenopausal osteoporosis to reduce the risk of hip fractures, treatment of osteoporosis in men at high risk of fractures, and treatment of Paget’s disease.

Risedronate sodium is a 1,1-bis(phosphonic acid).|Risedronate Sodium is the sodium salt of risedronic acid, a synthetic pyridinyl bisphosphonate. Risedronic acid binds to hydroxyapatite crystals in bone and inhibits osteoclast-dependent bone resorption.|A pyridine and diphosphonic acid derivative that acts as a CALCIUM CHANNEL BLOCKER and inhibits BONE RESORPTION.

Risedronate sodium Basic Attributes

Molecular Weight：

305.09

Exact Mass：

304.983032

EC Number：

1806241-263-5

UNII：

OFG5EXG60L

DSSTox ID：

DTXSID1046132

NCI Thesaurus Code：

C1528

HScode：

29333990

Characteristics

PSA：

148

XLogP3：

log Kow = -0.29 /Estimated/

Appearance：

white to beige

Melting Point：

252-262°C

Boiling Point：

692.3°C

Flash Point：

372.5ºC

Water Solubility：

H2O: soluble5mg/mL, clear (warmed)

Storage Conditions：

Store at RT

Vapor Pressure：

2.1X10-11 mm Hg at 25 °C /Estimated/

Safety Information

Transport codes：

NONH for all modes of transport

wgk germany：

hazard class code：

62-64

safety instructions：

20-22-36/37

RTECS Number：

SZ8567500

Precautionary statement(s)：

P280

Hazard Statements：

H302 + H312 + H332

GHS Classification：

|Warning|H302+H312+H332 (86.36%): Harmful if swallowed, in contact with skin or if inhaled [Warning Acute toxicity, oral; acute toxicity, dermal; acute toxicity, inhalation]|P261, P264, P270, P271, P280, P301+P312, P302+P352, P304+P312, P304+P340, P312, P322, P330, P363, and P501|Aggregated GHS information provided by 44 companies from 7 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.|H319 (100%): Causes serious eye irritation [Warning Serious eye damage/eye irritation]|P264, P280, P305+P351+P338, and P337+P313|The GHS information provided by 1 company from 1 notification to the ECHA C&L Inventory.

Drug Information

Drug Indication：

Treatment of osteoporosis

MeSH：

Agents that inhibit BONE RESORPTION and/or favor BONE MINERALIZATION and BONE REGENERATION. They are used to heal BONE FRACTURES and to treat METABOLIC BONE DISEASES such as OSTEOPOROSIS. (See all compounds classified as Bone Density Conservation Agents.)|A class of drugs that act by selective inhibition of calcium influx through cellular membranes. (See all compounds classified as Calcium Channel Blockers.)

MeSH Entry Terms：

1-Hydroxy-2-(3-pyridyl)ethylidene diphosphonate

Risedronate sodium Use and Manufacturing

Uses

Osteoporosis

Use Classification：

Human Drugs -> EU pediatric investigation plans|Human Drugs -> FDA Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book) -> Active Ingredients

Computed Properties

Molecular Weight:305.09
Hydrogen Bond Donor Count:4
Hydrogen Bond Acceptor Count:8
Rotatable Bond Count:4
Exact Mass:304.98301994
Monoisotopic Mass:304.98301994
Topological Polar Surface Area:151
Heavy Atom Count:18
Complexity:375
Undefined Atom Stereocenter Count:1
Covalently-Bonded Unit Count:2
Compound Is Canonicalized:Yes

Drug Function and Efficacy

It can bind to hydroxyapatite in bones and inhibit bone resorption. At the cellular level, this product inhibits osteoclasts, reduces bone turnover and absorption at bone remodeling sites, inhibits osteoclasts in osteoporosis model rats and miniature pigs, increases bone mass and bone biomechanical strength, and the increase in bone density is dose-related.

This ingredient has been used in drugs with the following functions (note: it does not mean that the ingredient itself has the following health functions)

Related Drugs

Risedronate Sodium Tablets
Ingredients	Risedronate
Indication	There are no reports of specific drug interactions for this product. This product is not metabolized, nor does it induce or inhibit hepatic cytochrome P450. Calcium/Antacids Taking this product with calcium, antacids, and oral preparations containing divalent cations will affect the absorption of this product. If hormone replacement therapy is used properly, this product can be used in combination with hormones. Aspirin/non-steroidal anti-inflammatory drugs In the Phase III clinical trial of this product involving 5,700 patients, 31% of the patients took aspirin, of which 24% took it regularly, and 48% of the patients took non-steroidal anti-inflammatory drugs, of which 21% took it regularly. The results showed that the incidence of upper gastrointestinal adverse reactions in patients taking aspirin/non-steroidal anti-inflammatory drugs was higher in the this product group (24.5%).
Specifications	5mg
Manufacturer	Topfond Pharmaceutical Co., Ltd.

Risedronate Sodium Tablets
Ingredients	Risedronate
Indication	There are no reports of specific drug interactions for this product. This product is not metabolized, nor does it induce or inhibit hepatic cytochrome P450. Calcium/Antacids Taking this product with calcium, antacids, and oral preparations containing divalent cations will affect the absorption of this product. If hormone replacement therapy is used properly, this product can be used in combination with hormones. Aspirin/non-steroidal anti-inflammatory drugs In the Phase III clinical trial of this product involving 5,700 patients, 31% of the patients took aspirin, of which 24% took it regularly, and 48% of the patients took non-steroidal anti-inflammatory drugs, of which 21% took it regularly. The results showed that the incidence of upper gastrointestinal adverse reactions in patients taking aspirin/non-steroidal anti-inflammatory drugs was higher in the this product group (24.5%).
Specifications	5mg
Manufacturer	Beijing SL Pharmaceutical Co., Ltd.

Risedronate
Manufacturer	Jiangsu Hansoh Pharmaceutical Group Co., Ltd.

See More Related Drugs

Registered Holders

ORBION PHARMACEUTICALS PRIVATE LTD

United States
Active
MACLEODS PHARMACEUTICALS LTD

India
Active
TAPI NL B.V.

France
Active

See More Registered Holders

Recommended Suppliers of Risedronate sodium

Hangzhou KieRay Chem Co.,LTD Contact Supplier

CN
5 YRS

Business licensed Certified factory

Manufactory Supplier of fine chemicals,pharmaceutical materials

Sodium risedronate

CAS No.: 115436-72-1

Grade: industrial Grade

Content: 98%

Inquiry
HANGZHOU TIANYE CHEMICALS CO., LTD Contact Supplier

CN
3 YRS

Business licensed

Trader Supplier of Di-n-butyl naphthalene-2,6-dicarboxylate

Sodium risedronate high purity

CAS No.: 115436-72-1

Grade: Pharmaceutical Grade

Content: 99%

Inquiry
Shandong Airuike Chemical Co., Ltd. Contact Supplier

CN
3 YRS

Business licensed

Trader Supplier of api,Intermediates,Organic Chemistry,Inorganic Chemistry,Daily Chemicals,Cosmetic Raw Materals,CATALYST AND AUXILIARY,FLAVORS AND FRAGRANCES,Chemical Pesticides,ADDITIVE

Hot sales Sodium Risedronate for Treatment of Osteoporosis CAS 115436-72-1

CAS No.: 115436-72-1

Grade: Pharmaceutical Grade

Content: 99%

Inquiry
Shandong Ailike New Material Technology Contact Supplier

CN
2 YRS

Business licensed

Trader Supplier of API,Antibiotics,Anti cancer category

High quality and low price Sodium Risedronate for Treatment of Osteoporosis CAS 115436-72-1

CAS No.: 115436-72-1

Grade: pharmaceutical grade

Content: 99.9%

Inquiry